Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Exelixis down 9% on Bristol-Myers' successful study of Opdivo + Yervoy in RCC

Published 09/07/2017, 12:41 PM
Updated 09/07/2017, 12:41 PM
© Reuters.  Exelixis down 9% on Bristol-Myers' successful study of Opdivo + Yervoy in RCC
  • Exelixis (EXEL -8.8%) is under pressure in apparent response to Bristol-Myers Squibb's announcement of positive results in a Phase 3 clinical trial assessing the combination of Opdivo and Yervoy in patients with advanced renal cell carcinoma.
  • Exelixis' top seller is CABOMETYX (cabozantinib), indicated for the same RCC patients as BMY's combo. It accounted for almost 82% of its Q2 revenues and 93% of its product sales.
  • In clinical studies, RCC patients treated with CABOMETYX experienced median progression-free survival (PFS) of 7.4 months and median overall survival (OS) of 21.4 months.
  • In BMY's study, patients receiving the Opdivo/Yervoy regimen showed median PFS of 11.6 months while OS had not been reached.
  • Previously: Opdivo-Yervoy combo extends survival in late-stage kidney cancer study; Bristol-Myers up 2% premarket (Sept. 7)
  • Now read: Opdivo's Renal Failure Boosts Exelixis - Or Does It?


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.